GlassScriptPhysician profile
Eitan S Burstein
NPI 1558621656
$5,211.03
in general payments reported to CMS, 2019-2025
25 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $174 · 2021: $66.37 · 2022: $446 · 2023: $1,177 · 2024: $1,875 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,170 · Travel and Lodging: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.99 |
| Travel and Lodging | $657.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $917.72 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Alcon Vision LLC | $848.02 | 2019-2025 | Rocklatan, Hydrus Microstent, Voyager Dslt |
| Carl Zeiss Meditec USA, INC. | $739.27 | 2024 | Cirrus Hd-Oct, Visumax, Veracity Surgical |
| Bausch & Lomb Americas INC. | $580.19 | 2022-2025 | Stellaris, Envista Mx60 Iol, Miebo |
| Glaukos Corporation | $447.08 | 2023-2024 | Radius Xr, Idose |
| Allergan, INC. | $389.44 | 2019-2021 | |
| Nova Eye, INC. | $273.12 | 2023 | |
| Sight Sciences, INC. | $174.26 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $164.87 | 2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Johnson & Johnson Surgical Vision, INC. | $150.00 | 2023 | Tecnis Iol, Catalys System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $149.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $66.56 | 2019 | |
| Halozyme INC | $50.76 | 2024 | Hylenex Recombinant |
| Boston Scientific Corporation | $38.54 | 2023-2024 | |
| Harrow Eye, LLC | $38.30 | 2024 | Vevye |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.08 | 2025 | Entyvio |
| Lombart Brothers, INC. | $28.63 | 2021 | |
| Aerie Pharmaceuticals, INC. | $23.11 | 2019 | |
| Thea Pharma INC. | $20.00 | 2025 | Iyuzeh |
| New World Medical,INC. | $19.80 | 2019-2022 | |
| Oyster Point Pharma, INC. | $19.32 | 2025 | Tyrvaya, Ryzumvi |
| Eyepoint US, INC. | $14.41 | 2019 | |
| Horizon Therapeutics Plc | $12.84 | 2023 | Uplizna |
| Eyevance Pharmaceuticals LLC | $12.40 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,901.92 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eitan Burstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.